Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Abeona Therapeutics (NASDAQ:ABEO) and maintained a price target of $18.
September 20, 2024 | 3:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Abeona Therapeutics, maintaining a price target of $18, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a high price target by a reputable analyst suggests a positive outlook for Abeona Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100